Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ASMBNASDAQ:EUDANYSE:HEXONASDAQ:NKTR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeASMBAssembly Biosciences$16.85-1.5%$12.64$7.75▼$19.93$128.69M0.5526,118 shs40,781 shsEUDAEUDA Health$3.71+9.8%$3.73$2.48▼$6.30$137.84M-0.0383,331 shs100,182 shsHEXOHEXO$0.71+2.5%$0.87$0.66▼$3.84$31.24M1.35880,508 shs305,500 shsNKTRNektar Therapeutics$8.59-1.9%$9.99$6.48▼$22.79$106.63M0.55135,933 shs441,266 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceASMBAssembly Biosciences0.00%+3.76%+34.80%+55.16%+8.64%EUDAEUDA Health0.00%+7.85%-6.08%-1.07%+53.94%HEXOHEXO0.00%0.00%0.00%0.00%0.00%NKTRNektar Therapeutics0.00%-14.01%-15.78%-36.14%-55.61%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationASMBAssembly Biosciences4.0391 of 5 stars3.35.00.04.71.70.80.0EUDAEUDA Health0.3991 of 5 stars0.03.00.00.02.00.00.6HEXOHEXON/AN/AN/AN/AN/AN/AN/AN/ANKTRNektar Therapeutics4.2014 of 5 stars3.54.00.04.22.22.50.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceASMBAssembly Biosciences 2.67Moderate Buy$33.0095.85% UpsideEUDAEUDA Health 4.00Strong BuyN/AN/AHEXOHEXO 0.00N/AN/AN/ANKTRNektar Therapeutics 3.00Buy$67.50685.80% UpsideCurrent Analyst Ratings BreakdownLatest HEXO, EUDA, NKTR, and ASMB Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/12/2025NKTRNektar TherapeuticsWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Perform4/11/2025NKTRNektar TherapeuticsJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold ➝ Buy$15.00 ➝ $30.003/25/2025ASMBAssembly BiosciencesGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$31.003/24/2025ASMBAssembly BiosciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral(Data available from 6/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookASMBAssembly Biosciences$32.15M4.00N/AN/A$7.50 per share2.25EUDAEUDA Health$4.01M34.36N/AN/A($0.30) per share-12.37HEXOHEXO$146.20M0.21N/AN/A$2.44 per share0.29NKTRNektar Therapeutics$87.25M1.22N/AN/A$0.69 per share12.45Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateASMBAssembly Biosciences-$61.23M-$6.23N/AN/AN/A-144.05%-121.46%-34.56%8/6/2025 (Estimated)EUDAEUDA Health-$10.04MN/A0.00N/AN/AN/AN/AN/A7/29/2025 (Estimated)HEXOHEXO-$845.90M-$5.21N/AN/AN/A-235.33%-74.04%-32.51%N/ANKTRNektar Therapeutics-$276.06M-$9.60N/AN/AN/A-180.70%-173.28%-46.31%8/6/2025 (Estimated)Latest HEXO, EUDA, NKTR, and ASMB EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025ASMBAssembly Biosciences-$2.01-$1.17+$0.84-$1.17$7.41 million$9.42 million5/8/2025Q1 2025NKTRNektar Therapeutics-$2.70-$3.30-$0.60-$0.24$15.61 million$10.46 million3/20/2025Q4 2024ASMBAssembly Biosciences-$1.75-$1.57+$0.18-$1.57$7.05 million$7.36 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthASMBAssembly BiosciencesN/AN/AN/AN/AN/AEUDAEUDA HealthN/AN/AN/AN/AN/AHEXOHEXON/AN/AN/AN/AN/ANKTRNektar TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioASMBAssembly BiosciencesN/A2.362.36EUDAEUDA HealthN/A0.13N/AHEXOHEXO0.010.410.24NKTRNektar TherapeuticsN/A4.244.24Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipASMBAssembly Biosciences19.92%EUDAEUDA Health4.35%HEXOHEXO7.78%NKTRNektar Therapeutics75.88%Insider OwnershipCompanyInsider OwnershipASMBAssembly Biosciences5.30%EUDAEUDA HealthN/AHEXOHEXO4.69%NKTRNektar Therapeutics5.25%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableASMBAssembly Biosciences1007.64 million6.03 millionOptionableEUDAEUDA Health237.15 millionN/ANot OptionableHEXOHEXO1,27744.00 million41.93 millionOptionableNKTRNektar Therapeutics22012.41 million177.62 millionOptionableHEXO, EUDA, NKTR, and ASMB HeadlinesRecent News About These CompaniesNektar Therapeutics (NASDAQ:NKTR) Given Consensus Recommendation of "Buy" by AnalystsJune 13 at 4:40 AM | marketbeat.comNektar Therapeutics (NASDAQ:NKTR) Short Interest UpdateJune 11, 2025 | marketbeat.comNektar Therapeutics: 2 Data Readouts For REZPEG 2025 Could Establish Further POCJune 11, 2025 | seekingalpha.comNektar Therapeutics (NASDAQ:NKTR) Shares Down 7.6% - Here's WhyJune 11, 2025 | marketbeat.comAMBROSIA & NEKTAR Introduces Premium High-End Organic Food from Greece with a Commitment to Purity and ProvenanceJune 10, 2025 | globenewswire.comNektar Therapeutics (NASDAQ:NKTR) Trading 12.1% Higher - What's Next?June 10, 2025 | marketbeat.comSquarepoint Ops LLC Purchases Shares of 139,758 Nektar Therapeutics (NASDAQ:NKTR)June 10, 2025 | marketbeat.comNektar Therapeutics (NASDAQ:NKTR) Sees Strong Trading Volume - Here's What HappenedJune 9, 2025 | marketbeat.comTop 10 Nasdaq Stocks by Performance According to KalkineJune 7, 2025 | kalkinemedia.comShort Interest in Nektar Therapeutics (NASDAQ:NKTR) Increases By 19.4%June 5, 2025 | marketbeat.comNektar Therapeutics Approves Reverse Stock SplitJune 4, 2025 | tipranks.comMackenzie Financial Corp Buys 417,651 Shares of Nektar Therapeutics (NASDAQ:NKTR)June 4, 2025 | marketbeat.comMillennium Management LLC Sells 536,773 Shares of Nektar Therapeutics (NASDAQ:NKTR)May 31, 2025 | marketbeat.comNatural Killer (NK)-Cell Lymphoma Pipeline Appears Robust With 100+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsightMay 29, 2025 | theglobeandmail.comNektar Therapeutics Elects New Board, Approves Key ProposalsMay 28, 2025 | tipranks.comNektar Therapeutics (NASDAQ:NKTR) Position Boosted by Woodline Partners LPMay 26, 2025 | marketbeat.comNektar Therapeutics (NASDAQ:NKTR) CEO Sells $15,549.36 in StockMay 22, 2025 | insidertrades.comNektar at H.C. Wainwright: Respag’s Promising FutureMay 21, 2025 | investing.comNektar Therapeutics (NASDAQ:NKTR) Receives Average Rating of "Buy" from BrokeragesMay 21, 2025 | marketbeat.comShay Capital LLC Sells 1,243,072 Shares of Nektar Therapeutics (NASDAQ:NKTR)May 19, 2025 | marketbeat.comOCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC Raises Stake in Nektar Therapeutics (NASDAQ:NKTR)May 16, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeHEXO, EUDA, NKTR, and ASMB Company DescriptionsAssembly Biosciences NASDAQ:ASMB$16.85 -0.25 (-1.46%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$16.55 -0.30 (-1.77%) As of 06/13/2025 06:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases. It develops ABI-5366, a long-acting herpes simplex virus (HSV) helicase-primase inhibitor that is in Phase 1a/1b clinical trial to treat recurrent genital herpes; ABI-1179, which is in Phase 1a/1b clinical trial for the treatment of recurrent genital herpes; and ABI-6250, a small molecule orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical trial. The company also develops ABI-4334, a next-generation capsid assembly modulator, which is in Phase 1b clinical trial for the treatment of hepatitis B virus (HBV). In addition, it develops an oral non-nucleoside polymerase inhibitor targeting transplant-related herpesviruses; and a small molecule interferon-a receptor agonist targeting HBV and HDV. The company has collaboration agreements with Gilead Sciences, Inc. and BeiGene, Ltd. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.EUDA Health NASDAQ:EUDA$3.71 +0.33 (+9.76%) Closing price 06/13/2025 03:59 PM EasternExtended Trading$3.78 +0.08 (+2.02%) As of 06/13/2025 06:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.EUDA Health Holdings Limited operates as a healthcare specialty company. The company operates through two segments, Medical Services and Property Management Services. It offers a range of specialty care services to patients; and operates medical facility general practice clinic that provides holistic care for various illnesses. The company is also involved in the property management that services shopping malls, business office building, or residential apartments. EUDA Health Holdings Limited is headquartered in Singapore.HEXO NYSE:HEXOHEXO Corp., together with its subsidiaries, produces, markets, and sells cannabis in Canada. The company offers its adult-use and medical products under the HEXO brand name. It also provides cannabis beverages under the Little Victory, House of Terpenes, Mollo, Veryvell, and XMG brands; and cannabis products under UP Cannabis, Original Stash, and Up brand names. It has a strategic alliance with Tilray Brands, Inc. The company was formerly known as The Hydropothecary Corporation and changed its name to HEXO Corp. in August 2018. HEXO Corp. was founded in 2013 and is headquartered in Gatineau, Canada. As of June 22, 2023, HEXO Corp. operates as a subsidiary of Tilray Brands, Inc.Nektar Therapeutics NASDAQ:NKTR$8.59 -0.17 (-1.94%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$8.66 +0.07 (+0.87%) As of 06/13/2025 07:18 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. The company was incorporated in 1990 and is headquartered in San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/09 - 06/13 Alphabet Enters a Bull Market: Is It Time to Buy? Ouster Soars 27% as DoD Grants First 3D LiDAR Approval for Drones RH Stock Rockets on Surprise Profit and Tariff Shift Super Micro Computer Stock: 2 Levels Smart Money Is Watching Intel's Price Spikes: Noise, or the First Notes of a Turnaround? IBM Up 10 Days in a Row: What’s Driving the Winning Streak? SoFi Stock’s Next Test: Can It Justify Its Premium Valuation? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
